 NESS ZIONA, Israel--BUSINESS WIRE--BiomX Inc. NYSE American: PHGE BiomX or the Company, a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided business updates for the first quarter ended March 31, 2021. We are off to a strong start in 2021 and are well-positioned to continue making solid progress throughout our entire pipeline of novel phage therapies with the 